This case study shows how category intelligence, cost transparency, and structured negotiations helped procurement leaders from a global pharmaceutical company move from reactive supplier relationships to confident, data-driven decisions. By implementing robust sourcing API workflows, the organization successfully mitigated market volatility while strengthening supply assurance.
Download the full case study to learn how procurement leaders:
-
Built true cost visibility using BOM-based cost models to inform their API sourcing strategies
-
Reduced dependency on single-source suppliers across critical APIs
-
Strengthened negotiation leverage with validated market benchmarks and diverse API sourcing strategies
-
Delivered savings without compromising supply continuity or compliance
Key metrics include:
Full methodology and outcomes revealed in the case study
Fill out the form on the right to download the Reshaping API sourcing to strengthen supply assurance
FAQs
1. What is API sourcing in pharmaceutical procurement?
In pharmaceutical procurement, strategic API sourcing refers to the process of identifying, evaluating, and acquiring Active Pharmaceutical Ingredients from reliable global manufacturers. Because APIs are the foundational components responsible for the therapeutic effects of medications, this sourcing process requires strict adherence to global regulatory standards, quality compliance, and rigorous supplier validation to prevent market shortages.
2. How can cost transparency improve procurement outcomes?
Achieving granular cost transparency procurement frameworks allows organizations to uncover hidden expenses across the end-to-end supply chain. By breaking down costs into raw materials, labor, logistics, and compliance, procurement teams can engage in fact-based supplier negotiations. This visibility eliminates arbitrary pricing, uncovers efficiency opportunities, and establishes more equitable, long-term supplier partnerships.
3. How do procurement teams reduce dependency on single-source suppliers?
To successfully eliminate single-source dependencies, enterprises must implement a proactive supplier diversification strategy. This involves mapping the entire supplier network to identify single points of failure and qualifying alternative, secondary vendors across different geographic regions. Spreading category spend across multiple vetted partners minimizes operational vulnerabilities and insulates production lines from localized disruptions.
4. What role does category intelligence play in procurement?
Utilizing robust category intelligence procurement tools equips decision-makers with real-time market data, pricing benchmarks, and macroeconomic trend analysis. Instead of relying on historical trends, procurement teams can leverage these predictive insights to anticipate market shifts, track regulatory changes, and optimize sourcing calendars. This intelligence transforms procurement from a transactional support function into a forward-looking revenue defender.
5. How can procurement balance cost savings with supply assurance?
Striking a balance between bottom-line savings and robust risk mitigation requires shifting toward a total value of ownership (TVO) model in supply assurance procurement. Rather than simply awarding contracts to the lowest bidder, organizations must weigh potential savings against cost factors like supplier reliability, lead times, and financial health. Investing in collaborative supplier relationships and strategic safety stock protects the enterprise from costly stockouts.
6. How does WNS Procurement help life sciences companies reshape their API sourcing to guarantee supply assurance?
WNS Procurement helps global life sciences organizations transform their supply chains by combining deep industry expertise with advanced digital toolkits. Through customized supplier diversification, automated risk tracking, and real-time category intelligence, WNS empowers pharmaceutical enterprises to optimize their cost structures while maintaining uncompromised regulatory compliance and absolute supply continuity for critical active ingredients.